Manufacturer record
Salus Pharmaceuticals 480/211: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Salus Pharmaceuticals 480/211 (Himachal Pradesh) were declared Not of Standard Quality between May 2025 and September 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: SPOT250033, Tamoxifen Tablets IP (exp Feb 2027). Government of NCT of Delhi (state lab) found it not of standard quality: Test for Dissolution. Listed in the September 2025 alert.
Records by type
2 records linked to Salus Pharmaceuticals 480/211 in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Tamoxifen Tablets IP | Batch SPOT250033Mfg Mar 2025 · Exp Feb 2027 | Test for DissolutionDissolution | Government of NCT of DelhiState lab | Sep 2025 |
| Misoprostol Tablets IP 200 mcg(Misotop 200) | Batch SPT241229Mfg Jun 2024 · Exp May 2026 | The content of Misoprostol in the sample is less (i.e 13.82% of the lablled amount) than the IP limitsOther | A.S Kambli Palghar-Zone-1 FDA, Lab MumbaiState lab | May 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.